Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Sep;70(9):1806-1808.
doi: 10.1136/gutjnl-2020-323366. Epub 2020 Nov 10.

Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis

Guo-Fu Li  1   2 , Xiao-Xiao An  2   3 , Yichao Yu  4 , Li-Rong Jiao  2   3 , Daniele Canarutto  5 , Guo Yu  6   2 , Guangji Wang  7 , Dan-Na Wu  8 , Yin Xiao  9
Affiliations
Comment

Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis

Guo-Fu Li et al. Gut. 2021 Sep.
No abstract available

Keywords: acid secretion; gastric acid; gastroesophageal reflux disease.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Forest plot showing the association between PPI use and SARS-CoV-2 infection. PPI, proton pump inhibitor.
Figure 2
Figure 2
Forest plot showing the association of PPI use with severe outcomes of COVID-19 (A, OR; B, HR) or duration of hospital stay (C). PPI, proton pump inhibitor.
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Lee SW, Ha EK, Yeniova Abdullah Özgür. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut 2021;70:807–9. 10.1136/gutjnl-2020-322248 - DOI - PubMed
    1. Almario CV, Chey WD, Spiegel BMR, et al. . Increased risk of COVID-19 among users of proton pump inhibitors. Am J Gastroenterol 2020;115:1707–15. 10.14309/ajg.0000000000000798 - DOI - PMC - PubMed
    1. Ullah A, Sivapalan L, Chelala PC, et al. . COVID-19 in patients with hepatobiliary and pancreatic diseases in East London: a single-centre cohort study. medRxiv 2020. - PMC - PubMed
    1. Vila-Corcoles A, Satue-Gracia E, Ochoa-Gondar O, et al. . Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: a population-based cohort study in southern Catalonia, Spain. J Clin Hypertens 2020. 10.1111/jch.13948. [Epub ahead of print: 25 Jul 2020]. - DOI - PMC - PubMed
    1. Huh K, Ji W, Kang M, et al. . Association of previous medications with the risk of COVID-19: a nationwide claims-based study from South Korea. medRxiv 2020.

Substances